Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.strides.com | |
Market Cap | 8,190.10 Cr. | |
Enterprise Value(EV) | 10,590.91 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -10.70 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.03 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 236.54 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 3.77 | Calculated using Price: 891.20 |
Dividend Yield | 0.17 | Period Ending 2023-03 |
No. of Shares Subscribed | 9.19 Cr. | 91,899,714 Shares |
FaceValue | 10 | |
About Strides Pharma Science Ltd. | ||
The company's core competence is in the development and manufacture of wide range of niche and technically complex pharmaceutical products. The company is also among the world's largest soft gelatin capsule manufacturers. |
1 Day |
|
-0.27% |
1 Week |
|
+6.13% |
1 Month |
|
+14.64% |
3 Month |
|
+36.45% |
6 Month |
|
+83.61% |
1 Year |
|
+173.42% |
2 Year |
|
+165.68% |
5 Year |
|
+87.27% |
10 Year |
|
+91.11% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 0.09 | 6.22 | 10.37 | 2.86 | 3.5 | 1.68 | 9.21 | -18.49 | -10.15 | |
Return on Capital Employed (%) | 10.92 | 7.98 | 8.32 | 4.83 | 2.61 | 4.06 | 9.08 | -9.49 | -0.49 | |
Return on Assets (%) | 0.04 | 2.4 | 3.63 | 1.02 | 1.24 | 0.63 | 3.82 | -6.99 | -3.52 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 1,145 | 2,658 | 2,749 | 2,464 | 2,649 | 2,527 | 2,777 | 2,359 | 2,212 | 2,054 | |
Non Curr. Liab. | 286 | 2,760 | 2,049 | 2,067 | 2,343 | 814 | 1,264 | 966 | 1,210 | 916 | |
Curr. Liab. | 1,020 | 1,892 | 3,104 | 1,896 | 2,662 | 2,545 | 2,738 | 3,412 | 2,990 | 3,138 | |
Minority Int. | 19 | 50 | 134 | 155 | 153 | 67 | 37 | 24 | -39 | -60 | |
Equity & Liab. | 2,469 | 7,360 | 8,035 | 6,585 | 7,807 | 5,953 | 6,817 | 6,761 | 6,373 | 6,047 | |
Non Curr. Assets | 1,040 | 3,845 | 4,243 | 4,101 | 4,758 | 3,581 | 4,000 | 3,399 | 3,130 | 2,658 | |
Curr. Assets | 1,429 | 3,515 | 3,792 | 2,447 | 3,049 | 2,371 | 2,817 | 3,362 | 3,135 | 3,389 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 2,469 | 7,360 | 8,035 | 6,585 | 7,807 | 5,953 | 6,817 | 6,761 | 6,373 | 6,047 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 1,196 | 2,862 | 2,755 | 2,845 | 2,178 | 2,752 | 3,316 | 3,070 | 3,688 | 3,953 | |
Other Income | 39 | 92 | 161 | 88 | 41 | 53 | 59 | 133 | 135 | 80 | |
Total Income | 1,234 | 2,954 | 2,917 | 2,933 | 2,219 | 2,805 | 3,375 | 3,204 | 3,824 | 4,034 | |
Total Expenditure | -967 | -2,448 | -2,228 | -2,443 | -1,936 | -2,236 | -2,689 | -3,092 | -3,303 | -3,284 | |
PBIDT | 267 | 506 | 688 | 491 | 283 | 569 | 686 | 112 | 521 | 749 | |
Interest | -47 | -168 | -183 | -196 | -79 | -156 | -150 | -177 | -261 | -315 | |
Depreciation | -64 | -131 | -126 | -154 | -117 | -174 | -206 | -233 | -243 | -232 | |
Taxation | -148 | -42 | -63 | -6 | 27 | -11 | -32 | 178 | 55 | -19 | |
Exceptional Items | -7 | -41 | -36 | -44 | 22 | -78 | 43 | -244 | -17 | -188 | |
PAT | 1 | 118 | 280 | 74 | 89 | 43 | 244 | -474 | -231 | -5 | |
Minority Interest | 1 | 14 | -46 | -20 | -5 | 6 | 11 | 14 | 10 | 20 | |
Share Associate | -168 | ||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 845 | 109 | 400 | 665 | 325 | 36 | 268 | -460 | -203 | -98 | |
Adjusted EPS | 142 | 12 | 45 | 74 | 36 | 4 | 30 | -51 | -22 | -11 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | -272 | 83 | 73 | 288 | 187 | 60 | 205 | 481 | -258 | 44 | |
Cash Fr. Inv. | 4,077 | 52 | -2,225 | -687 | 583 | -148 | 1,306 | -521 | -119 | 302 | |
Cash Fr. Finan. | -3,319 | -421 | 2,944 | 338 | -1,016 | 194 | -1,709 | -16 | 421 | -214 | |
Net Change | 487 | -286 | 792 | -60 | -246 | 106 | -199 | -55 | 45 | 133 | |
Cash & Cash Eqvt | 586 | 298 | 1,111 | 515 | 256 | 366 | 182 | 126 | 171 | 304 |
Tue, 09 Apr 2024
Press Release Strides Pharma Science Limited has informed the Exchange regarding a press release dated April 09, 2024, titled Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg. |
Sat, 06 Apr 2024
Updates Strides Pharma Science Limited has informed the Exchange regarding 'Completion of US-FDA Inspection at the Formulations Facility of Strides Alathur Private Limited, a wholly owned subsidiary of the Company'. |
Fri, 29 Mar 2024
Copy of Newspaper Publication Newspaper Advertisement of the Notice of Postal Ballot |
Tue, 23 Apr 2024 |
Higher Delivery Quantity |
Higher Trade Quantity |
Higher Trade and Delivery Quantity |
Close Crossing 52 Week High |
Opening at Low |